临床研究

miRNAs调节的免疫炎性机制在脊髓损伤致骨质疏松症患者发病中的调控机制

  • 陈聪 ,
  • 邢槐杰 ,
  • 陈敏 ,
  • 曾超胜 ,
  • 苏庆杰
展开
  • 海南医学院第二附属医院 (海口 570311 )

收稿日期: 2023-04-14

  网络出版日期: 2023-11-22

基金资助

海南省卫生健康委员会科研项目(21A200002)

Regulatory role of miRNAs in the pathogenesis of osteoporosis induced by spinal cord injury

  • Cong CHEN ,
  • Huaijie XING ,
  • Min CHEN ,
  • Chaosheng ZENG ,
  • Qingjie. SU
Expand
  • The Second Affiliated Hospital,Hainan Medical College,Haikou 570311,China

Received date: 2023-04-14

  Online published: 2023-11-22

摘要

目的 探究微小RNAs(miRNAs)调节的免疫炎性机制在脊髓损伤致骨质疏松症(CSCI-OP)发病中的调控机制。 方法 收集30例CSCI-OP患者为脊髓损伤组,选50例老年性骨质疏松患者为老年骨质疏松组,选50例健康体检人群为正常对照组。对比各组激素指标、炎症因子、miRNAs表达、生物信息学分析的变化,探究影响CSCI-OP患者发病的主要因素。 结果 与脊髓损伤组对比,老年骨质疏松组的睾酮(T)、肿瘤坏死因子-α(TNF-α)水平上升,雌二醇(E2)、白细胞介素-6(IL-6)、骨性碱性磷酸酶(BLAP)水平下降(P<0.05);而两组的25羟基维生素D(25-OHD)、甲状旁腺激素(PTH)水平对比,但差异无统计学意义(P>0.05)。单因素分析显示CSCI-OP发生主要与年龄、性别、脊髓损伤病程、糖尿病有关(P < 0.05)。与正常对照组相比,老年骨质疏松组、脊髓损伤组的IL-6 miRNA、BLAP miRNA表达升高,TNF-α miRNA表达下降(P < 0.05)。 结论 miRNAs在CSCI-OP中可有效调节,且通过靶向免疫炎性机制能明显减缓CSCI-OP的发生及发展。

本文引用格式

陈聪 , 邢槐杰 , 陈敏 , 曾超胜 , 苏庆杰 . miRNAs调节的免疫炎性机制在脊髓损伤致骨质疏松症患者发病中的调控机制[J]. 实用医学杂志, 2023 , 39(19) : 2483 -2488 . DOI: 10.3969/j.issn.1006-5725.2023.19.012

Abstract

Objective To explore the regulatory role of immunoinflammatory mechanism regulated by tiny RNAs (miRNAs) in the pathogenesis of spinal cord injury-induced osteoporosis (CSCI-OP). Methods Thirty patients with CSCI-OP admitted to our hospital from July 2021 to July 2022 were selected as the observation group, fifty patients with senile osteoporosis were selected as the control group, and fifty healthy people were selected as the normal control group. The three groups were compared in terms of hormone indexes, inflammatory factors, miRNAs expression and bioinformatics analysis. The main factors affecting the pathogenesis of CSCI-OP patients were detected. Results Compared with the spinal cord injury group, the T and TNF-α levels were increased, and the E2, IL-6 and BLAP levels were decreased in the senile osteoporosis group (P < 0.05), but there was no significant difference in 25-OHD and PTH levels between the two groups (P > 0.05). Univariate analysis showed that the incidence of CSCI-OP was mainly related to age, sex, duration of spinal cord injury and diabetes mellitus (P < 0.05). Compared with the normal control group, the expression of IL-6 miRNA and BLAP miRNA in the control group and observation group was increased and the expression of TNF-α miRNA was decreased (P < 0.05). Conclusion MiRNAs can be effectively regulated in CSCI-OP. It can significantly slow down the occurrence and development of CSCI-OP through targeted immune inflammatory mechanisms.

参考文献

1 ANJUM A, YAZID M D, FAUZI DAUD M, et al. Spinal Cord Injury: Pathophysiology, Multimolecular Interactions, and Underlying Recovery Mechanisms[J]. Int J Mol Sci,2020,21(20):7533.
2 QUADRI S A, FAROOQUI M, IKRAM A, et al. Recent update on basic mechanisms of spinal cord injury[J]. Neurosurg Rev,2020,43(2):425-441.
3 SINGH S, DUTTA S, KHASBAGE S, et al. A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis[J]. Osteoporos Int,2022,33(1):1-12.
4 WAN Y, ZENG F, TAN H, et al. Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review[J]. Osteoporos Int,2022,33(5):979-1015.
5 BELLAVIA D, SALAMANNA F, RAIMONDI L, et al. Deregulated miRNAs in osteoporosis: effects in bone metastasis[J]. Cell Mol Life Sci,2019,76(19):3723-3744.
6 YANG Y, YU J W, FANG W, et al. The roles of miRNA, lncRNA and circRNA in the development of osteoporosis[J]. Biol Res,2020,53(1):40.
7 TOMINAGA A, WADA K, OKAZAKI K, et al. Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment[J]. Osteoporos Int,2022,33(6):1265-1273.
8 HACHMANN J T, YOUSAK A, WALLNER J J, et al. Epidural spinal cord stimulation as an intervention for motor recovery after motor complete spinal cord injury[J]. J Neurophysiol,2021,126(6):1843-1859.
9 HE J, XU S, ZHANG B, et al. Gut microbiota and metabolite alterations associated with reduced bone mineral density or bone metabolic indexes in postmenopausal osteoporosis[J]. Aging (Albany NY),2020,12(9):8583-8604.
10 陈少华,赖培茜,林定坤,等. 林氏健体八段功对骨质疏松患者平衡功能及生存质量的影响[J]. 实用医学杂志,2021,37(3):400-404,409.
11 YONG E L, LOGAN S. Menopausal osteoporosis: screening, prevention and treatment[J]. Singapore Med J,2021,62(4):159-166.
12 MUNOZ M, ROBINSON K, SHIBLI-RAHHAL A. Bone Health and Osteoporosis Prevention and Treatment[J]. Clin Obstet Gynecol,2020,63(4):770-787.
13 DE MARTINIS M, GINALDI L, ALLEGRA A, et al. The Osteoporosis/Microbiota Linkage: The Role of miRNA[J]. Int J Mol Sci,2020,21(23):8887.
14 KO N Y, CHEN L R, CHEN K H. The Role of Micro RNA and Long-Non-Coding RNA in Osteoporosis[J]. Int J Mol Sci,2020,21(14):4886.
15 GENG Q, GAO H, YANG R, et al. Pyrroloquinoline Quinone Prevents Estrogen Deficiency-Induced Osteoporosis by Inhibiting Oxidative Stress and Osteocyte Senescence[J]. Int J Biol Sci,2019,15(1):58-68.
16 杨淮叶,狄丹华. 更年骨坚方治疗绝经后骨质疏松症(肝肾阴虚型)对患者血清Leptin、BGP、E2水平的影响[J]. 四川中医,2020,38(9):165-167.
17 DE PAIVA GONCALVES V, CABRERA-ORTEGA A A, CARVALHO J S, et al. Physiological testosterone replacement effects on male aged rats with orchiectomy-induced osteoporosis in advanced stage: a tomographic and biomechanical pilot study[J]. Aging Male,2021,24(1):139-147.
18 AGGARWAL V, MUTHUKRISHNAN J, MANRAI M, et al. The prevalence of osteoporosis and its association with serum testosterone and serum vitamin D in the elderly male population: A cross-sectional study[J]. Med J Armed Forces India,2023,79(2):189-193.
19 楚永杰,王猛,邱翔. 黄芪补肝益肾汤联合阿仑膦酸钠片治疗老年骨质疏松症的临床疗效及对患者炎症因子、骨密度的影响[J]. 河南中医,2021,41(4):581-584.
24 吴钒,吴华珍,黄志辉,等. 补肾壮骨丸对初次椎体成形术后伤椎再塌陷的防治作用[J]. 实用医学杂志,2022,38(1):111-115.
文章导航

/